{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:57:25Z","timestamp":1793120245997,"version":"4.5.0"},"reference-count":130,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2021,3,1]]},"DOI":"10.1001\/jamapsychiatry.2020.3643","type":"journal-article","created":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T11:38:50Z","timestamp":1606304330000},"page":"270","source":"Crossref","is-referenced-by-count":200,"title":["Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure"],"prefix":"10.1001","volume":"78","author":[{"given":"Filip","family":"Milosavljevic","sequence":"first","affiliation":[{"name":"Department of Physiology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikola","family":"Bukvic","sequence":"additional","affiliation":[{"name":"Department of Physiology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zorana","family":"Pavlovic","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, University of Belgrade, Belgrade, Serbia"},{"name":"Psychiatry Clinic, Clinical Centre of Serbia, Belgrade"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedo","family":"Miljevic","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, University of Belgrade, Belgrade, Serbia"},{"name":"Institute for Mental Health, Belgrade, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Pe\u0161ic","sequence":"additional","affiliation":[{"name":"Department of Physiology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen","family":"Molden","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics, University of Oslo Pharmacy School, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Ingelman-Sundberg","sequence":"additional","affiliation":[{"name":"Pharmacogenetics Section, Department of Physiology and Pharmacology, Karolinska Institutet, Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Technische Universit\u00e4t M\u00fcnchen School of Medicine, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marin M.","family":"Jukic","sequence":"additional","affiliation":[{"name":"Department of Physiology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia"},{"name":"Pharmacogenetics Section, Department of Physiology and Pharmacology, Karolinska Institutet, Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"yoi200068r1","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"issue":"7","key":"yoi200068r2","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S2215-0366(19)30217-2","article-title":"Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis.","volume":"6","author":"Furukawa","year":"2019","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"yoi200068r3","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1176\/appi.ajp.2019.19010034","article-title":"Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia.","volume":"177","author":"Leucht","year":"2020","journal-title":"Am J Psychiatry"},{"issue":"5","key":"yoi200068r4","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1176\/appi.ajp.2017.17050550","article-title":"Impact of CYP2C19 genotype on escitalopram exposure and therapeutic failure: a retrospective study based on 2,087 patients.","volume":"175","author":"Jukic","year":"2018","journal-title":"Am J Psychiatry"},{"issue":"5","key":"yoi200068r5","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S2215-0366(19)30088-4","article-title":"Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study.","volume":"6","author":"Jukic","year":"2019","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"yoi200068r6","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/s41386-019-0554-x","article-title":"Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients.","volume":"45","author":"Br\u00e5ten","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"yoi200068r7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/gim.2016.80","article-title":"Prediction of CYP2D6 phenotype from genotype across world populations.","volume":"19","author":"Gaedigk","year":"2017","journal-title":"Genet Med"},{"issue":"2","key":"yoi200068r8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/tpj.2015.70","article-title":"Interethnic variation of CYP2C19 alleles, \u201cpredicted\u201d phenotypes and \u201cmeasured\u201d metabolic phenotypes across world populations.","volume":"16","author":"Fricke-Galindo","year":"2016","journal-title":"Pharmacogenomics J"},{"issue":"4","key":"yoi200068r9","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/cpt.690","article-title":"Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects.","volume":"102","author":"Zhou","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"yoi200068r10","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.euroneuro.2018.05.009","article-title":"Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies.","volume":"28","author":"Fabbri","year":"2018","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"yoi200068r11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4088\/JCP.v66n0103","article-title":"The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation.","volume":"66","author":"de Leon","year":"2005","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"yoi200068r12","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/mp.2016.204","article-title":"Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment.","volume":"22","author":"Jukic","year":"2017","journal-title":"Mol Psychiatry"},{"issue":"2","key":"yoi200068r13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00414-018-1927-0","article-title":"Completed suicides of citalopram users-the role of CYP genotypes and adverse drug interactions.","volume":"133","author":"Rahikainen","year":"2019","journal-title":"Int J Legal Med"},{"key":"yoi200068r14","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104620","article-title":"Translation of pharmacogenomic drug labels into the clinic: current problems.","volume":"153","author":"Ingelman-Sundberg","year":"2020","journal-title":"Pharmacol Res"},{"issue":"10128","key":"yoi200068r15","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"issue":"9896","key":"yoi200068r16","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"yoi200068r17","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"yoi200068r18","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/cts.v13.1","article-title":"Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group.","volume":"13","author":"Caudle","year":"2020","journal-title":"Clin Transl Sci"},{"issue":"15","key":"yoi200068r19","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting: Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"issue":"1","key":"yoi200068r20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1471-2288-8-32","article-title":"The ratio of means method as an alternative to mean differences for analyzing continuous outcome variables in meta-analysis: a simulation study.","volume":"8","author":"Friedrich","year":"2008","journal-title":"BMC Med Res Methodol"},{"key":"yoi200068r22","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials.","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"issue":"2","key":"yoi200068r24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00228-015-1965-1","article-title":"Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol.","volume":"72","author":"Lisbeth","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"yoi200068r25","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/bcpt.2018.122.issue-6","article-title":"Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 polymorphisms on pharmacokinetics and safety of aripiprazole in healthy volunteers.","volume":"122","author":"Belmonte","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"3","key":"yoi200068r26","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/JCP.0000000000000319","article-title":"The influence of the CYP3A4*22 polymorphism and CYP2D6 polymorphisms on serum concentrations of aripiprazole, haloperidol, pimozide, and risperidone in psychiatric patients.","volume":"35","author":"van der Weide","year":"2015","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"yoi200068r27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00228-019-02768-0","article-title":"Impact of age and CYP2D6 genetics on exposure of aripiprazole and dehydroaripiprazole in patients using long-acting injectable versus oral formulation: relevance of poor and intermediate metabolizer status.","volume":"76","author":"Tveito","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"yoi200068r28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/FTD.0b013e3182031021","article-title":"Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.","volume":"33","author":"Suzuki","year":"2011","journal-title":"Ther Drug Monit"},{"issue":"5","key":"yoi200068r29","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1097\/FTD.0000000000000070","article-title":"Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.","volume":"36","author":"Suzuki","year":"2014","journal-title":"Ther Drug Monit"},{"issue":"6","key":"yoi200068r30","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/pcn.2012.66.issue-6","article-title":"Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia.","volume":"66","author":"Nagai","year":"2012","journal-title":"Psychiatry Clin Neurosci"},{"issue":"1","key":"yoi200068r31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00228-011-1094-4","article-title":"The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.","volume":"68","author":"Azuma","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"yoi200068r32","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2133\/dmpk.20.55","article-title":"Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole.","volume":"20","author":"Kubo","year":"2005","journal-title":"Drug Metab Pharmacokinet"},{"issue":"5","key":"yoi200068r33","doi-asserted-by":"publisher","first-page":"358","DOI":"10.2133\/dmpk.22.358","article-title":"Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism.","volume":"22","author":"Kubo","year":"2007","journal-title":"Drug Metab Pharmacokinet"},{"issue":"2","key":"yoi200068r34","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/sj.tpj.6500160","article-title":"Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6.","volume":"3","author":"Desai","year":"2003","journal-title":"Pharmacogenomics J"},{"issue":"13","key":"yoi200068r35","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.2217\/pgs.13.150","article-title":"Relationship between CYP2D6 genotype and haloperidol pharmacokinetics and extrapyramidal symptoms in healthy volunteers.","volume":"14","author":"Gass\u00f3","year":"2013","journal-title":"Pharmacogenomics"},{"issue":"4","key":"yoi200068r36","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1067\/mcp.2002.127494","article-title":"The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.","volume":"72","author":"Brockm\u00f6ller","year":"2002","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"yoi200068r37","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/JCP.0b013e31802e68d5","article-title":"Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism.","volume":"27","author":"Troost","year":"2007","journal-title":"J Clin Psychopharmacol"},{"issue":"11","key":"yoi200068r38","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00228-010-0850-1","article-title":"The role of CYP2D6 and ABCB1 pharmacogenetics in drug-na\u00efve patients with first-episode schizophrenia treated with risperidone.","volume":"66","author":"Jovanovic","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"yoi200068r39","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1097\/JCP.0b013e3181c17df0","article-title":"Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone.","volume":"29","author":"Hendset","year":"2009","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"yoi200068r40","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.euroneuro.2017.03.012","article-title":"Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients.","volume":"27","author":"Mas","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"yoi200068r41","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00228-014-1664-3","article-title":"Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients.","volume":"70","author":"Mannheimer","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"yoi200068r42","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2217\/pgs.13.204","article-title":"Effect of CYP2D6 on risperidone pharmacokinetics and extrapyramidal symptoms in healthy volunteers: results from a pharmacogenetic clinical trial.","volume":"15","author":"Gass\u00f3","year":"2014","journal-title":"Pharmacogenomics"},{"issue":"3","key":"yoi200068r43","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s002130051171","article-title":"Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.","volume":"147","author":"Scordo","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"yoi200068r44","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1055\/s-2007-973836","article-title":"A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.","volume":"40","author":"Leon","year":"2007","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"yoi200068r45","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/JCP.0b013e3181ee84c7","article-title":"Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers.","volume":"30","author":"Novalbos","year":"2010","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"yoi200068r46","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/hup.v29.5","article-title":"Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers.","volume":"29","author":"Cabaleiro","year":"2014","journal-title":"Hum Psychopharmacol"},{"issue":"2","key":"yoi200068r47","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1055\/s-2002-25026","article-title":"The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients.","volume":"35","author":"Bondolfi","year":"2002","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"yoi200068r48","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1177\/0091270009347867","article-title":"Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety.","volume":"50","author":"Xiang","year":"2010","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"yoi200068r49","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.clpt.2005.07.007","article-title":"Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.","volume":"78","author":"Jung","year":"2005","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"yoi200068r50","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/hup.v24:4","article-title":"Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia.","volume":"24","author":"Yagihashi","year":"2009","journal-title":"Hum Psychopharmacol"},{"issue":"2","key":"yoi200068r51","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1177\/0091270002239819","article-title":"Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.","volume":"43","author":"Yasui-Furukori","year":"2003","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"yoi200068r52","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/JCP.0b013e3181a289e0","article-title":"Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients.","volume":"29","author":"Kang","year":"2009","journal-title":"J Clin Psychopharmacol"},{"issue":"9","key":"yoi200068r53","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s002280100372","article-title":"Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients.","volume":"57","author":"Roh","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"yoi200068r54","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/hup.1260","article-title":"Effect of the cytochrome P450 2D6*10 allele on risperidone metabolism in Japanese psychiatric patients.","volume":"27","author":"Suzuki","year":"2012","journal-title":"Hum Psychopharmacol"},{"issue":"2b","key":"yoi200068r55","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/bph.2011.164.issue-2b","article-title":"Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10\/*10.","volume":"164","author":"Yoo","year":"2011","journal-title":"Br J Pharmacol"},{"issue":"3","key":"yoi200068r56","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/00007691-200306000-00006","article-title":"Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia.","volume":"25","author":"Mihara","year":"2003","journal-title":"Ther Drug Monit"},{"issue":"6","key":"yoi200068r57","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/BF02969428","article-title":"Pharmacokinetics and bioequivalence evaluation of risperidone in healthy male subjects with different CYP2D6 genotypes.","volume":"29","author":"Cho","year":"2006","journal-title":"Arch Pharm Res"},{"issue":"2","key":"yoi200068r58","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/00004714-200004000-00005","article-title":"Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline.","volume":"20","author":"Morita","year":"2000","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"yoi200068r59","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/01.ftd.0000211823.80854.db","article-title":"Sequence-based CYP2D6 genotyping in the Korean population.","volume":"28","author":"Lee","year":"2006","journal-title":"Ther Drug Monit"},{"issue":"4","key":"yoi200068r60","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/S0009-9236(98)90069-8","article-title":"Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes.","volume":"64","author":"Yue","year":"1998","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"yoi200068r61","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s00228-015-1855-6","article-title":"Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems.","volume":"71","author":"Chen","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"yoi200068r62","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s00228-004-0792-6","article-title":"Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine.","volume":"60","author":"Sawamura","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"yoi200068r63","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1067\/mcp.2000.106128","article-title":"Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects.","volume":"67","author":"Yoon","year":"2000","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"yoi200068r64","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00228-002-0529-3","article-title":"CYP2D6*10 alleles do not determine plasma fluvoxamine concentration\/dose ratio in Japanese subjects.","volume":"58","author":"Ohara","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"yoi200068r65","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00228-009-0629-4","article-title":"Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine-alprazolam interaction in patients with psychosomatic disease.","volume":"65","author":"Sugahara","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"yoi200068r66","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/00007691-200308000-00008","article-title":"Effects of the CYP 2D6 genotype and cigarette smoking on the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients.","volume":"25","author":"Gerstenberg","year":"2003","journal-title":"Ther Drug Monit"},{"issue":"6","key":"yoi200068r67","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1097\/FTD.0b013e31818d73b3","article-title":"Dose-dependent effect of the CYP2D6 genotype on the steady-state fluvoxamine concentration.","volume":"30","author":"Watanabe","year":"2008","journal-title":"Ther Drug Monit"},{"issue":"2","key":"yoi200068r68","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1248\/bpb.33.285","article-title":"Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine concentration in plasma of Japanese patients.","volume":"33","author":"Katoh","year":"2010","journal-title":"Biol Pharm Bull"},{"issue":"7","key":"yoi200068r69","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1177\/0269881110370504","article-title":"CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics.","volume":"25","author":"Suzuki","year":"2011","journal-title":"J Psychopharmacol"},{"issue":"5","key":"yoi200068r70","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1097\/JCP.0b013e3182664d98","article-title":"Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression.","volume":"32","author":"Sirot","year":"2012","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"yoi200068r71","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2165\/0003088-200948010-00005","article-title":"Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour.","volume":"48","author":"Lind","year":"2009","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"yoi200068r72","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1097\/01.jcp.0000145341.30547.f0","article-title":"Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers.","volume":"24","author":"Kirchheiner","year":"2004","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"yoi200068r73","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/tpj.2012.29","article-title":"Use of pharmacogenetics in bioequivalence studies to reduce sample size: an example with mirtazapine and CYP2D6.","volume":"13","author":"Gonz\u00e1lez-Vacarezza","year":"2013","journal-title":"Pharmacogenomics J"},{"issue":"2","key":"yoi200068r74","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/01.jcp.0000203199.88581.c3","article-title":"Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects.","volume":"26","author":"Park","year":"2006","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"yoi200068r75","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/00008571-199710000-00013","article-title":"Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients.","volume":"7","author":"Suzuki","year":"1997","journal-title":"Pharmacogenetics"},{"issue":"3","key":"yoi200068r76","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0009-9236(99)70108-6","article-title":"Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia.","volume":"65","author":"Mihara","year":"1999","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"yoi200068r77","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1046\/j.0306-5251.2001.01437.x","article-title":"Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients.","volume":"52","author":"Roh","year":"2001","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"yoi200068r78","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1046\/j.1440-1819.1999.00611.x","article-title":"The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population.","volume":"53","author":"Someya","year":"1999","journal-title":"Psychiatry Clin Neurosci"},{"issue":"6","key":"yoi200068r79","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/S0278-5846(03)00154-4","article-title":"Effects of smoking and cytochrome P450 2D6*10 allele on the plasma haloperidol concentration\/dose ratio.","volume":"27","author":"Ohara","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"4","key":"yoi200068r80","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1097\/00007691-200008000-00005","article-title":"CYP2D6*10 alleles are not the determinant of the plasma haloperidol concentrations in Asian patients.","volume":"22","author":"Shimoda","year":"2000","journal-title":"Ther Drug Monit"},{"issue":"3","key":"yoi200068r81","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/00041444-200309000-00005","article-title":"Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients.","volume":"13","author":"Inada","year":"2003","journal-title":"Psychiatr Genet"},{"issue":"8","key":"yoi200068r82","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/sj.npp.1300213","article-title":"Effect of CYP2D6 genotypes on the metabolism of haloperidol in a Japanese psychiatric population.","volume":"28","author":"Someya","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"yoi200068r83","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00228-007-0453-7","article-title":"Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele.","volume":"64","author":"Hermann","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"yoi200068r84","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/(ISSN)1099-1166","article-title":"CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly.","volume":"21","author":"Whyte","year":"2006","journal-title":"Int J Geriatr Psychiatry"},{"issue":"3","key":"yoi200068r85","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2165\/11586630-000000000-00000","article-title":"Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50?mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.","volume":"31","author":"Nichols","year":"2011","journal-title":"Clin Drug Investig"},{"issue":"5","key":"yoi200068r86","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/jcp.2006.31.issue-5","article-title":"CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.","volume":"31","author":"Shams","year":"2006","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"yoi200068r87","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/JCP.0b013e318192e4c1","article-title":"Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.","volume":"29","author":"Preskorn","year":"2009","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"yoi200068r88","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/JCP.0000000000001174","article-title":"The influence of combined CYP2D6 and CYP2C19 genotypes on venlafaxine and O-desmethylvenlafaxine concentrations in a large patient cohort.","volume":"40","author":"Kringen","year":"2020","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"yoi200068r89","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s002280050737","article-title":"The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population.","volume":"56","author":"Fukuda","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"yoi200068r90","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1007\/s00213-014-3825-6","article-title":"The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes.","volume":"232","author":"Jiang","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"yoi200068r91","doi-asserted-by":"publisher","first-page":"537","DOI":"10.2217\/pgs.09.168","article-title":"Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.","volume":"11","author":"Tsai","year":"2010","journal-title":"Pharmacogenomics"},{"issue":"2","key":"yoi200068r92","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/0269881113512041","article-title":"Genetic differences in cytochrome P450 enzymes and antidepressant treatment response.","volume":"28","author":"Hodgson","year":"2014","journal-title":"J Psychopharmacol"},{"issue":"3","key":"yoi200068r93","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/FTD.0000000000000506","article-title":"Effects of cytochrome P450 (CYP) 2C19 genotypes on steady-state plasma concentrations of escitalopram and its desmethyl metabolite in Japanese patients with depression.","volume":"40","author":"Tsuchimine","year":"2018","journal-title":"Ther Drug Monit"},{"issue":"12","key":"yoi200068r94","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00228-008-0533-3","article-title":"Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients.","volume":"64","author":"Rudberg","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"yoi200068r95","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/bcpt.2018.122.issue-5","article-title":"Effect of polymorphisms on the pharmacokinetics, pharmacodynamics and safety of sertraline in healthy volunteers.","volume":"122","author":"Saiz-Rodr\u00edguez","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"yoi200068r96","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41397-019-0108-y","article-title":"Impact of CYP1A2, CYP2C19, and CYP2D6 genotype- and phenoconversion-predicted enzyme activity on clozapine exposure and symptom severity.","volume":"20","author":"Lesche","year":"2020","journal-title":"Pharmacogenomics J"},{"issue":"4","key":"yoi200068r97","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/JCP.0b013e3181acc372","article-title":"ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.","volume":"29","author":"Sirot","year":"2009","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"yoi200068r98","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1177\/0706743716670128","article-title":"Genetic determinants of clozapine-induced metabolic side effects.","volume":"62","author":"Vasudev","year":"2017","journal-title":"Can J Psychiatry"},{"issue":"7","key":"yoi200068r99","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/ijnp\/pyx019","article-title":"Potential role of patients\u2019 CYP3A-status in clozapine pharmacokinetics.","volume":"20","author":"T\u00f3th","year":"2017","journal-title":"Int J Neuropsychopharmacol"},{"issue":"10","key":"yoi200068r100","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1111\/bcp.v86.10","article-title":"The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple-dose trial.","volume":"86","author":"Koller","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"yoi200068r101","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1177\/0004563216686377","article-title":"Quantification of the steady-state plasma concentrations of clozapine and N-desmethylclozapine in Japanese patients with schizophrenia using a novel HPLC method and the effects of CYPs and ABC transporters polymorphisms.","volume":"54","author":"Akamine","year":"2017","journal-title":"Ann Clin Biochem"},{"issue":"2","key":"yoi200068r102","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/cts.2017.10.issue-2","article-title":"A Study on CYP2C19 and CYP2D6 polymorphic effects on pharmacokinetics and pharmacodynamics of amitriptyline in healthy Koreans.","volume":"10","author":"Ryu","year":"2017","journal-title":"Clin Transl Sci"},{"issue":"1","key":"yoi200068r103","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/bcp.2008.65.issue-1","article-title":"The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population.","volume":"65","author":"Halling","year":"2008","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"yoi200068r104","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1373\/clinchem.2003.030825","article-title":"Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers.","volume":"50","author":"Steimer","year":"2004","journal-title":"Clin Chem"},{"issue":"2","key":"yoi200068r105","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00228-002-0445-6","article-title":"The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects.","volume":"58","author":"Jiang","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"yoi200068r106","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1055\/s-00000054","article-title":"Factors affecting steady-state plasma concentrations of enantiomeric mirtazapine and its desmethylated metabolites in Japanese psychiatric patients.","volume":"48","author":"Hayashi","year":"2015","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"yoi200068r107","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1097\/00007691-200312000-00014","article-title":"Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine.","volume":"25","author":"Charlier","year":"2003","journal-title":"Ther Drug Monit"},{"issue":"10","key":"yoi200068r108","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2165\/11318050-000000000-00000","article-title":"Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy.","volume":"48","author":"Ververs","year":"2009","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"yoi200068r109","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0009-9236(98)90040-6","article-title":"10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes.","volume":"63","author":"Dal\u00e9n","year":"1998","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"yoi200068r110","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/bcp.2004.57.issue-4","article-title":"Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes.","volume":"57","author":"Yasui-Furukori","year":"2004","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"yoi200068r111","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/pto.2005.97.issue-5","article-title":"Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.","volume":"97","author":"Scordo","year":"2005","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"3","key":"yoi200068r112","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/00004714-200106000-00013","article-title":"Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers.","volume":"21","author":"Eap","year":"2001","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"yoi200068r113","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1046\/j.0306-5251.2001.01402.x","article-title":"Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects.","volume":"52","author":"Liu","year":"2001","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"yoi200068r114","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/FTD.0000000000000135","article-title":"Impact of genetic variability in CYP2D6, CYP3A5, and ABCB1 on serum concentrations of quetiapine and N-desalkylquetiapine in psychiatric patients.","volume":"37","author":"Bakken","year":"2015","journal-title":"Ther Drug Monit"},{"issue":"7","key":"yoi200068r115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-analyses: the PRISMA statement.","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"11","key":"yoi200068r116","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1177\/0269881118798605","article-title":"Effects of aripiprazole on pupillometric parameters related to pharmacokinetics and pharmacogenetics after single oral administration to healthy subjects.","volume":"32","author":"Koller","year":"2018","journal-title":"J Psychopharmacol"},{"issue":"9","key":"yoi200068r117","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1176\/appi.ajp.2018.17111282","article-title":"Clinical implementation of pharmacogenetic decision support tools for antidepressant drug prescribing.","volume":"175","author":"Zeier","year":"2018","journal-title":"Am J Psychiatry"},{"issue":"3","key":"yoi200068r118","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/mp.2012.42","article-title":"Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function.","volume":"18","author":"Stingl","year":"2013","journal-title":"Mol Psychiatry"},{"issue":"6","key":"yoi200068r119","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S2215-0366(16)00017-1","article-title":"Commercial pharmacogenetic-based decision-support tools in psychiatry.","volume":"3","author":"Bousman","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"yoi200068r126","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/acps.2018.137.issue-1","article-title":"Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia.","volume":"137","author":"McCutcheon","year":"2018","journal-title":"Acta Psychiatr Scand"},{"issue":"6","key":"yoi200068r127","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/JCP.0000000000001131","article-title":"Dopamine D2 receptor occupancy estimated from plasma concentrations of four different antipsychotics and the subjective experience of physical and mental well-being in schizophrenia: results from the randomized NeSSy Trial.","volume":"39","author":"Veselinovic","year":"2019","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"yoi200068r128","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12888-017-1412-1","article-title":"Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial.","volume":"17","author":"P\u00e9rez","year":"2017","journal-title":"BMC Psychiatry"},{"key":"yoi200068r129","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jpsychires.2017.09.024","article-title":"Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: a randomized clinical trial demonstrating clinical utility.","volume":"96","author":"Bradley","year":"2018","journal-title":"J Psychiatr Res"},{"key":"yoi200068r130","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jpsychires.2019.01.003","article-title":"Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: a large, patient- and rater-blinded, randomized, controlled study.","volume":"111","author":"Greden","year":"2019","journal-title":"J Psychiatr Res"},{"key":"yoi200068r21","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions, version 6.1 (updated September 2020)","author":"Higgins","year":"2020"},{"key":"yoi200068r23","volume-title":"Bioavailability and Bioequivalence Studies for Orally Administered Drug Products\u2014General Considerations","author":"Guidance for Industry","year":"2003"},{"key":"yoi200068r120","unstructured":"US Food and Drug Administration. Risperidal drug label. Published June 2009. Accessed June 20, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020272s056,020588s044,021346s033,021444s03lbl.pdf?"},{"key":"yoi200068r121","unstructured":"US Food and Drug Administration. Abilify drug label. Published August 2016. Accessed June 30, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021436s041,021713s032,021729s024,021866s026lbl.pdf"},{"key":"yoi200068r122","unstructured":"US Food and Drug Administration. Lexapro drug label. Published January 2017. Accessed June 30, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021323s047lbl.pdf?"},{"key":"yoi200068r123","unstructured":"US Food and Drug Administration. Zoloft drug label. Published December 2016. Accessed June 30, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/019839S74S86S87_20990S35S44S45lbl.pdf?"},{"key":"yoi200068r124","unstructured":"US Food and Drug Administration. Paxil drug label. Published December 2012. Accessed June 30, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020031s067,020710s031.pdf?"},{"key":"yoi200068r125","unstructured":"US Food and Drug Administration. Pamelor drug label. Published May 2007. Accessed June 30, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/018013s58lbl.pdf?"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2773579\/jamapsychiatry_milosavljevi_2020_oi_200068_1614611265.78507.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T11:12:44Z","timestamp":1614769964000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2773579"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":130,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.3643","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.739101641.793580741","asserted-by":"object"}]},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,1]]}}}